Evidence map›Paper›PMID 25483673›Full record

ReviewHuman vaccines & immunotherapeutics2014

Tecemotide: an antigen-specific cancer immunotherapy.

Gregory T Wurz, Chiao-Jung Kao, Michael Wolf, Michael W DeGregorio

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Nanoparticles in Clinical Translation for Cancer Therapy.International journal of molecular sciences · 2022
    Review
  11. Review
  12. The Nanosystems Involved in Treating Lung Cancer.Life (Basel, Switzerland) · 2021
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Occurrence of pneumonitis following radiotherapy of breast cancer - A prospective study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018
    Article
  18. Molecular characterization ofCold Spring Harbor molecular case studies · 2018
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gregory T Wurza University of California , Davis; Department of Internal Medicine; Division of Hematology and Oncology ; Sacramento , CA USA.
Chiao-Jung Kao
Michael Wolf
Michael W DeGregorio

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of tumor-associated antigens (TAA) has made possible the development of antigen-specific cancer immunotherapies such as tecemotide. One of those is mucin 1 (MUC1), a cell membrane glycoprotein expressed on some epithelial tissues such as breast and lung. In cancer, MUC1 becomes overexpressed and aberrantly glycosylated, exposing the immunogenic tandem repeat units in the extracellular domain of MUC1. Designed to target tumor associated MUC1, tecemotide is being evaluated in Phase III clinical trials for treatment of unresectable stage IIIA/IIIB non-small cell lung cancer (NSCLC) as maintenance therapy following chemoradiotherapy. Additional Phase II studies in other indications are ongoing. This review discusses the preclinical and clinical development of tecemotide, ongoing preclinical studies of tecemotide in human MUC1 transgenic mouse models of breast and lung cancer, and the potential application of these models for optimizing the timing of chemoradiotherapy and tecemotide immunotherapy to achieve the best treatment outcome for patients.

Indexed as

AnimalsAntigens, NeoplasmBreast NeoplasmsCancer VaccinesCarcinoma, Non-Small-Cell LungChemoradiotherapyDisease Models, AnimalFemaleHumansImmunotherapyLung NeoplasmsMembrane GlycoproteinsMiceMice, TransgenicMucin-1Antigens, NeoplasmCancer VaccinesL-BLP25Membrane GlycoproteinsMUC1 protein, humanMucin-1ADT, androgen deprivation therapyAPC, antigen presenting cellASI, active specific immunotherapyBSC, best supportive careCEA, carcinoembryonic antigenChemoradiotherapyCI, confidence intervalCONSORT, consolidated standards of reporting trialsCPA, cyclophosphamideCRT, chemoradiotherapyCTL, Cytotoxic T-lymphocyteDMPG, Dimyristoyl phosphatidylglycerolDPPC, Dipalmitoyl phosphatidylcholineDTH, delayed-type hypersensitivityECOG, Eastern cooperative oncology groupELISpot, enzyme-linked immunosorbent spotFACT-L, functional assessment of cancer therapy-lungGy, grayHLA, human lymphocyte antigenHR, hazard ratioIFN-γ, interferon gammaIgG, immunoglobulin GIL-2, Interleukin 2immunotherapyINSPIRE, stimuvax trial in Asian NSCLC patients: stimulating immune responseITT, intent to treati.v., intravenousKLH, keyhole limpet hemocyaninLICC, L-BLP25 in colorectal cancerLR, locoregionalMAP, multiple antigenic peptideMHC, major histocompatibility complexMMT, muc1-expressing mammary tumorMPLA, monophosphoryl lipid AMUC1MUC1, Mucin 1MUC1.Tg, MUC1 transgenicnon-small cell lung cancerNSCLC, non-small cell lung cancerOH-BBN, N-butyl-N-(4-hydroxybutyl)nitrosamineOS, overall survivalPBL, peripheral blood lymphocytesPCR, pathological complete remissionPSA, prostate specific antigenPyV-mT, polyomavirus middle-TQOL, quality of lifeRCB, residual cancer burdenRECIST, response evaluation criteria in solid tumorsRTX, radiotherapySTART, stimulating targeted antigenic responses to NSCLCTAA, tumor associated antigentecemotideTGF-β, transforming growth factor βTH1, T-helper type ITH2, T-helper type IITNF-α, tumor necrosis factor αTOI, trial outcome indexVNTR, variable number of tandem repeats

Identifiers

PMID25483673
PMCPMC4514140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.